ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Health Canada Approves Upadacitinib to Treat Adults with PsA

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2021

Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.

Filed under:Drug Updates Tagged with:Canadadrug approvalsPsApsoriatic arthritisupadacitinib

Grinding Away: An Overview of Progress in the Treatment & Management of Osteoarthritis

Jason Liebowitz, MD, FACR  |  June 28, 2021

Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:dietary supplementEULARhandhand osteoarthritisKnee Osteoarthritis (OA)osteoarthritis (OA)

Insight into the Biosimilar Prescribing Habits of Rheumatologists

Michele B. Kaufman, PharmD, BCGP  |  June 23, 2021

The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsInternationalprescriptionprescription habitsrheumatologists

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARoutcomeOutcome measurespsoriatic arthritis

Are Medicare Beneficiaries with Knee OA Receiving Enough Conservative Care?

Marilynn Larkin  |  June 22, 2021

NEW YORK (Reuters Health)—Non-surgical care for knee osteoarthritis (OA) is uncommon among older adults, especially in regions of the U.S. where total knee arthroplasty rates are high, a large retrospective analysis shows.1 “As rheumatologists, we often think of knee arthroplasty as the last resort, after patients have tried and failed more conservative treatments, such as…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & RheumatologyKnee Osteoarthritis (OA)patient caretotal knee arthroplasty

Case Report: Does a Young Woman with Gitelman Syndrome Have Gout?

Rebecca Lindsey Weiner, DO, & Ann K. Rosenthal, MD, FACP  |  June 14, 2021

Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:case reportGitelman SyndromeGout

Case Report: Saddle Nose Deformity in IgG4-Related Disease

Alyxandra Soloway, MD, & Stephen Soloway, MD, FACP, FACR  |  June 14, 2021

Immunoglobulin G4-related disease (IgG4-related disease) is relatively rare, although with greater recognition it is becoming more frequently diagnosed. Some of the more common presentations of the disease include aortitis, cholangitis, autoimmune pancreatitis, sclerosing sialadenitis, orbital disease with proptosis and subacute mass development in the affected organ.1 It has protean manifestations and is diagnosed by classic…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportIgG4 related diseasesaddle nose deformity

Studies Probe Treating Rheumatoid Arthritis with Vagus Nerve Stimulation

Jason Liebowitz, MD, FACR  |  June 14, 2021

When rheumatologists think about rheumatoid arthritis (RA), they are apt to picture the synovium, contemplate such antibodies as rheumatoid factor and those to citrullinated proteins, and consider how this interplay of factors manifests in disease. What is not as commonly discussed is the role the autonomic nervous system plays in the pathogenesis and symptomatology of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:vagus nerve stimulation

Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2021

Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptinjection pensyringeYLB113-002

The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab

Michele B. Kaufman, PharmD, BCGP  |  May 24, 2021

As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsdenosumabEB1001monoclonal antibody

  • « Previous Page
  • 1
  • …
  • 67
  • 68
  • 69
  • 70
  • 71
  • …
  • 247
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences